Veralox Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
18
- Latest Deal Type
-
2ndary - Private
- Investors
-
14
Veralox Therapeutics General Information
Description
Developer of small molecule therapeutics designed to target heparin-induced thrombocytopenia and thrombosis. The company's therapeutics focus on new treatment paradigms and improved outcomes for patients based on the understanding of the molecular mechanisms of diabetes diseases, enabling patients to achieve complete recovery from diabetes.
Contact Information
Website
www.veralox.comCorporate Office
- 4539 Metropolitan Court
- Frederick, MD 21704
- United States
Corporate Office
- 4539 Metropolitan Court
- Frederick, MD 21704
- United States
Veralox Therapeutics Timeline
Veralox Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Secondary Transaction - Private | 01-Jan-2026 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 4. Later Stage VC | 23-Sep-2025 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series B) | 21-Jun-2023 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series A) | 10-Jun-2021 | $16.6M | $16.6M | Completed | Clinical Trials - General | |
| 1. Grant | 18-Oct-2018 | $319K | Completed | Clinical Trials - General |
Veralox Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Veralox Therapeutics Comparisons
Industry
Financing
Details
Veralox Therapeutics Competitors (26)
One of Veralox Therapeutics’s 26 competitors is Meditope Biosciences, a Formerly VC-backed company based in Pasadena, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Meditope Biosciences | Formerly VC-backed | Pasadena, CA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| IDEAYA Biosciences | Formerly VC-backed | South San Francisco, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Precigen | Formerly VC-backed | Germantown, MD |
Veralox Therapeutics Patents
Veralox Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025207887-A1 | Methods for treating heparin-induced thrombocytopenia | Pending | 27-Mar-2024 | ||
| AU-2024312215-A1 | Compositions and methods of use to treat 12-lipoxygenase (12-lox) mediated diseases | Pending | 22-Jun-2023 | ||
| EP-4731206-A2 | Compositions and methods of use to treat 12-lipoxygenase (12-lox) mediated diseases | Pending | 22-Jun-2023 | ||
| WO-2024264032-A2 | Compositions and methods of use to treat 12-lipoxygenase (12-lox) mediated diseases | Inactive | 22-Jun-2023 | ||
| WO-2024264032-A3 | Compositions and methods of use to treat 12-lipoxygenase (12-lox) mediated diseases | Inactive | 22-Jun-2023 | C07D417/12 |
Veralox Therapeutics Signals
Veralox Therapeutics Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Pappas Capital | Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Alumni Ventures | Venture Capital | Minority | ||
| Genesys Capital | Venture Capital | Minority | ||
| Point Field Partners | Family Office | Minority |
Veralox Therapeutics FAQs
-
When was Veralox Therapeutics founded?
Veralox Therapeutics was founded in 2017.
-
Where is Veralox Therapeutics headquartered?
Veralox Therapeutics is headquartered in Frederick, MD.
-
What is the size of Veralox Therapeutics?
Veralox Therapeutics has 18 total employees.
-
What industry is Veralox Therapeutics in?
Veralox Therapeutics’s primary industry is Drug Discovery.
-
Is Veralox Therapeutics a private or public company?
Veralox Therapeutics is a Private company.
-
What is Veralox Therapeutics’s current revenue?
The current revenue for Veralox Therapeutics is .
-
How much funding has Veralox Therapeutics raised over time?
Veralox Therapeutics has raised $41.2M.
-
Who are Veralox Therapeutics’s investors?
Pappas Capital, Alexandria Venture Investments, Alumni Ventures, Genesys Capital, and Point Field Partners are 5 of 14 investors who have invested in Veralox Therapeutics.
-
Who are Veralox Therapeutics’s competitors?
Meditope Biosciences, Inovio Pharmaceuticals, IDEAYA Biosciences, Adaptimmune Therapeutics, and Precigen are some of the 26 competitors of Veralox Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process